文献速递脑血管病

慢性肾脏病患者口服抗凝治疗的系统综述与荟萃分析

Oral anticoagulation in patients with chronic kidney disease: A systematic review and meta-analysis.
PubMed 文献 · Neurology · 2019-05-08

该系统综述与荟萃分析纳入15项研究共78,053例慢性肾脏病患者,比较华法林与无抗凝、以及NOAC与华法林的效果。结果显示华法林较无抗凝降低缺血性卒中与死亡风险,NOAC较华法林降低颅内出血、卒中或系统性栓塞及大出血风险。

要点

  • 慢性肾脏病患者华法林较无抗凝降低缺血性卒中与死亡风险
  • NOAC较华法林显著降低颅内出血、卒中或系统性栓塞及大出血风险
  • Xa因子抑制剂较华法林一致降低合并卒中、死亡、颅内出血及大出血风险

核心结论

  • 在慢性肾脏病口服抗凝患者中,NOAC在多种心血管结局上呈现更优的安全性与有效性特征。

研究设计与样本

  • 系统综述与荟萃分析,纳入15项研究共78,053例慢性肾脏病患者,其中7项比较NOAC与华法林、8项比较华法林与无抗凝。
  • 慢性肾脏病按肌酐清除率定义:轻度60-89 mL/min、中度30-59 mL/min、重度15-29 mL/min。

主要发现

  • 华法林较无抗凝降低缺血性卒中风险(RR=0.68;95%CI 0.55-0.84)和死亡风险(RR=0.70;95%CI 0.62-0.78)。
  • NOAC较华法林降低颅内出血风险(RR=0.43;95%CI 0.33-0.56)、合并卒中风险(RR=0.83;95%CI 0.72-0.96)、卒中或系统性栓塞风险(RR=0.73;95%CI 0.62-0.85)及大出血风险(RR=0.77;95%CI 0.66-0.90)。
  • 校正分析中,华法林较无抗凝降低死亡风险(HRadj=0.68;95%CI 0.61-0.76),NOAC较华法林降低颅内出血风险(HRadj=0.39;95%CI 0.30-0.50)及卒中或系统性栓塞风险(HRadj=0.75;95%CI 0.65-0.88)。
  • 敏感性分析显示,Xa因子抑制剂较华法林一致降低合并卒中风险(RR=0.84;95%CI 0.73-0.96)、死亡风险(RR=0.84;95%CI 0.70-1.00)、颅内出血风险(RR=0.45;95%CI 0.24-0.85)及大出血风险(RR=0.76;95%CI 0.64-0.91)。

临床怎么用

  • 对慢性肾脏病合并抗凝指征患者,可优先考虑NOAC以降低颅内出血与大出血风险。
  • 无抗凝禁忌时,华法林较不用抗凝可降低缺血性卒中与死亡风险,但需权衡出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Data regarding the efficacy and safety of warfarin and non-vitamin K antagonist oral anticoagulant (NOAC) among patients with chronic kidney disease (CKD) remain scarce. METHODS: Systematic review and meta-analysis of studies involving patients with CKD treated with oral anticoagulants were conducted to evaluate the following outcomes: ischemic stroke, intracerebral hemorrhage (ICH), combined ischemic and hemorrhagic stroke (strokecombined), stroke or systemic embolism, mortality, and major bleeding events. CKD was defined based on creatinine clearance (CrCl) ranging from mild (CrCl: 60-89 mL/min), moderate (CrCl: 30-59 mL/min), to severe (CrCl: 15-29 mL/min). RESULTS: Fifteen studies (7 comparing NOAC vs warfarin and 8 comparing warfarin vs no anticoagulant) were identified comprising 78,053 patients. Warfarin (vs no anticoagulant) was associated with reduced risk of ischemic stroke (risk ratio [RR] = 0.68; 95% confidence interval [CI] 0.55-0.84]) and mortality (RR = 0.70; 95% CI 0.62-0.78). In comparison to warfarin, NOAC use lowered the risk of ICH (RR = 0.43; 95% CI 0.33-0.56), strokecombined (RR = 0.83; 95% CI 0.72-0.96), stroke or systemic embolism (RR = 0.73; 95% CI 0.62-0.85), and major bleeding (RR = 0.77; 95% CI 0.66-0.90). In adjusted analyses, warfarin use (vs no anticoagulant) was associated with reduced mortality (HRadj = 0.68; 95% CI 0.61-0.76), whereas NOAC (vs warfarin) use reduced the risk of ICH (HRadj = 0.39; 95% CI 0.30-0.50) and stroke or systemic embolism (HRadj = 0.75; 95% CI 0.65-0.88). Our sensitivity analyses comparing different NOACs exhibited that factor Xa inhibitors (compared to warfarin) consistently reduced strokecombined (RR = 0.84; 95% CI 0.73-0.96), mortality (RR = 0.84; 95% CI 0.70-1.00), ICH (RR = 0.45; 95% CI 0.24-0.85), and major bleeding (RR = 0.76; 95% CI 0.64-0.91). CONCLUSIONS: Among patients with CKD treated with oral anticoagulants, NOACs present with a more favorable safety and efficacy profile for various cardiovascular outcomes.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Malhotra K, Ishfaq MF, Goyal N, et al. Oral anticoagulation in patients with chronic kidney disease: A systematic review and meta-analysis. Neurology. 2019. PMID: 31068485. doi:10.1212/WNL.0000000000007534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。